Mitsui Fudosan (8801.T) traded up 2.23 % during a 24 hours period ending at 06:23 PM Central Europe on Monday 26th. One Mitsui Fudosan stock can currently be bought for about JPY 1,637.5 on popular exchanges. Current supply of Mitsui Fudosan stocks is 2.7 bn. Mitsui Fudosan has a current market capitalization of JPY 4.3 trillions and approximately JPY 29.1 bn worth of Mitsui Fudosan was traded on exchanges in the last 24 hours. Since last month end, Mitsui Fudosan has traded 5.4 % up. Simple moving average of last 200 days is at JPY 1,649.3. The highest price of past 52 weeks was recorded at JPY 2,158 on 02/12/2026. 52 weeks low was at JPY 1,400 on 10/09/2026.

Here is how related stocks have performed in the past 24 hours:

  • Ajinomoto (2802.T) traded up 0.36 % and now trades at JPY 5,013. Ajinomoto has a market capitalisation of JPY 4.8 trillions. Ajinomoto has a current price to earnings ratio of 34.97.

  • Ibiden (4062.T) traded down -1 % and now trades at JPY 8,248. Ibiden has a market capitalisation of JPY 4.8 trillions. Current price/earnings ratio for Ibiden is 72.53.

  • Denso (6902.T) traded down -0.24 % and now trades at JPY 1,854.5. Current market capitalisation for Denso is JPY 4.6 trillions. Current price/earnings ratio for Denso is 11.51.

  • Mitsubishi Estate (8802.T) traded up 2.76 % and now trades at JPY 3,939. Current market capitalisation for Mitsubishi Estate is JPY 4.7 trillions. Mitsubishi Estate has a current price to earnings ratio of 16.37.

  • Astellas Pharma (4503.T) traded up 0.98 % and now trades at JPY 2,558.5. Current market capitalisation for Astellas Pharma is JPY 4.5 trillions. Current price/earnings ratio for Astellas Pharma is 12.36. AstraZeneca’s experimental stomach‑cancer drug, an antibody‑drug conjugate called sone‑ve, has shown a significant improvement in patient survival in a late‑stage trial, according to a report presented at the European Society for Medical Oncology meeting. The study indicated that patients with advanced gastric cancer who received the treatment lived substantially longer than those on standard chemotherapy, particularly when the drug was used after two prior lines of therapy. While the therapy did not appear to delay disease progression, it was associated with a lower incidence of severe side effects compared with older treatments. AstraZeneca is in discussions with health authorities about the data and is exploring the drug’s potential as a new standard of care for advanced gastric cancer. The company’s broader research pipeline also includes a promising combination therapy for non‑small‑cell lung cancer that demonstrated extended survival and manageable safety in early trials.

About Mitsui Fudosan

Mitsui Fudosan Co., Ltd. is a real estate service company operating in Japan with its main office located in Chuo-Ku. The company offers a comprehensive range of real estate-related services such as leasing, subdivision, construction, sales, and maintenance of office buildings and residential houses. In addition, it manufactures building materials, operates commercial facilities including hotels and golf places, and provides financial services such as the securitization of real estate properties. You can find more information about their services and initiatives on their website at www.mitsuifudosan.co.jp . The company is listed on the Tokyo Stock Exchange. It had its initial public offering (IPO) on May 1, 1949.